Trending Topic

23 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Luke G Qin, Michael T Pierce, Rachel C Robbins

The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part of the eye, such as the vitreous or peripheral retina. The clinical taxonomy of uveitis […]

John A Hovanesian, AAO 2020 – The D3 Study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 27th 2020

It was a pleasure to speak with our valued Editorial Board member, John A Hovanesian (Harvard Eye Associates, Laguna Hills, CA, USA), about his AAO 2020 poster presentation on the D3 study, evaluating dexamethasone intraocular suspension versus prednisolone acetate 1%.

Questions

  1. What are the challenges of topical medications after cataract surgery? (00:06)
  2. Could you tell us a little about dexamethasone intraocular suspension and its advantages compared with standard topical medications? (01:05)
  3. What were the aims and design of your study? (01:42)
  4. What were the major findings of your study? (02:48)
  5. What are the implications of these findings for clinical practice? (04:58)

Speaker Disclosure: Dr John A Hovanesian has provided paid consultancy for 1-800-DOCTORS, Acufocus, Aerie Pharmaceutical, Alcon, Allegro Ophthalmics, Allergan, Abbott Medical Optics, BlephEx, Eyedetec, Glaukos, Guardion Health Sciences, IOP/Katena, Ivantis, Kala Pharma, Novartis, Ocular Therapeutix, Omeros, ReVision Optics, Sarentis ophthalmics, Sensimed, Shire, Tearlab, Tear Film Innovations, Valeant, Veracity and Vindico Medical Education. He has served on medical advisory boards for 1-800-DOCTORS, Aerie Pharmaceutical, Abbott Medical Optics, BlephEx, Cord, LLC, Eyedetec, Glaukos, Guardion Health Sciences, Ingenoeye, IOP/Katena, Ivantis, Kala Pharma, MDbackline, Ocular Therapeautix, Omeros, ReVision Optics, Shire, Sight Sciences, Tearlab, Tear Film Innovations, Valeant and Veracity. He has conducted paid research for Acufocus, Aerie Pharmaceutical, Alcon, Allergan, Abbott Medical Optics, Cloudbreak Therapeutics, Cord, LLC, Eyedetec, Glaukos, Ingenoeye, IOP/Katena, Novartis, Ocular Therapeutix, Omeros, ReVision Optics, Shire, Tear Film Innovations and Valeant. He also has equity interest in Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, BlephEx, Eyedetec, Glaukos, Guardion Health Sciences, Harvard Eye Associates, Harvard Hearing, Ingenoeye, MDbackline, Novartis, Ocular Therapeutix, RxSight, Sarentis Ophthalmics, Sight Sciences and Tear Film Innovations. He has received royalties from sales from Slack Books and TLC The Laser Center. No financial interest exists for prescribing, recommending, or using a particular product in patient care. This list may not be complete because of financial interests that may arise between updates to this document or stock ownership through mutual funds, exchange traded funds, or other vehicles that do not involve a direct relationship with the entity.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of AAO 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup